In pancreatic carcinomas, IL-33 drives ILC2 activation, which promotes CD103+ dendric cell recruitment through the production of CCL-5 and, consequently, CD8+ T cell activation [33]. This evidence concerns the gene CCL5 and exocrine pancreatic carcinoma.